Luulyo 2021: Breyanzi (Lisocabtagene maraleucel; liso-cel), resepter-ga cusub ee CD19-ku hagaayo chimeric antigen (CAR) Daaweynta unugyada T horumariyo by Bristol Myers Squibb (BMS), waxaa ansixiyay Maamulka Cuntada iyo Dawooyinka ee Maraykanka (USFDA).
Daaweynta unugyada CAR-T waa nooc ka mid ah difaaca jirka oo ka shaqeeya beddelka unugyada T qofka si loo aqoonsado loona burburiyo unugyada kansarka.
Breyanzi, daawaynta unugga cusub ee CD19-directed chimeric antigen receptor (CAR) oo ay samaysay Bristol Myers Squibb (BMS), ayaa lagu ansixiyay Maamulka Cuntada iyo Dawooyinka ee Mareykanka (USFDA) (Lisocabtagene maraleucel; liso-cel).
Sidoo kale akhri: CAR T-Cell daaweynta Hindiya
Bukaannada qaangaarka ah ee leh dib u soo noqoshada ama dib u laabashada (R/R) weyn ee lymphoma B-cell (LBCL) ka dib laba ama in ka badan oo daawaynta habdhiska ah ayaa lagu daweyn doonaa kan cusub Daaweynta unugyada CAR T. Waxaa jira dhowr nooc oo LBCL ah, sida dhexdhexaadinta aasaasiga ah ee weyn ee B-cell lymphoma, heerka sare ee lymphoma B-cell, lymphoma fasalka 3B, iyo DLBCL oo aan si kale loo sharaxin, kuwaas oo sidoo kale ka soo bixi kara lymphoma-ka-dabiiciga ah.
Kansarka DLBCL waa nooca ugu badan ee non-Hodgkin lymfoma (NHL), waana jirro daran kaas oo boqolkiiba 73 bukaannada aysan ka jawaabin daaweynta ama soo noqnoqda.
Breyanzi, dhanka kale, laguma talinayo bukaanka qaba nidaamka dhexe ee neerfayaasha lymphoma, inkastoo xaqiiqda ah in ay tahay daaweyn suurtagal ah.
Sidoo kale akhri: CAR T-Cell daaweynta Shiinaha
Breyanzi, a Daaweynta unugyada CAR T, will be very important in clinical practice, giving people with relapsed or refractory large B-cell lymphoma the chance for a long-lasting response with a personalized treatment experience, said Samit Hirawat, chief medical officer at Bristol Myers Squibb. Our unwavering commitment to advancing cell therapy research, providing breakthrough medicines, and supporting patients at every step of their treatment journey is reflected in the FDA approval.”
Breyanzi waxa uu lahaa boqolkiiba 73 heerka jawaabta guud iyo 54 boqolkiiba jawaab celinta dhammays tiran (CR) ee daraasadda TRANSCEND NHL 001, taas oo ahayd tijaabadii ugu weyneyd ee 3L+ LBCL.
BMS’ immunotherapy manufacturing plant in Bothell, Washington, will produce the novel cell treatment.
CAR T-Cell daaweynta Hindiya Waxay ku jirtaa marxaladda tijaabooyinka bukaan-socodka, waxaana rajeyneynaa in si dhaqso ah loo heli doono isticmaalka ganacsiga.
